Background Non-alcoholic fatty liver disease (NAFLD) is rapidly becoming a global health
problem. Cardiovascular diseases (CVD) are the most common cause of mortality in NAFLD …

Fatty liver associated with metabolic dysfunction is common, affects a quarter of the
population, and has no approved drug therapy. Although pharmacotherapies are in …

We report a genome-wide association study (GWAS) of coronary artery disease (CAD)
incorporating nearly a quarter of a million cases, in which existing studies are integrated with …

Nonalcoholic fatty liver (NAFL) and its sequelae are growing health problems. We performed
a genome-wide association study of NAFL, cirrhosis and hepatocellular carcinoma, and …

Nonalcoholic fatty liver disease (NAFLD) is common and partially heritable and has no
effective treatments. We carried out a genome-wide association study (GWAS) meta …

Abstract Background and Aims The risk factors of cholelithiasis have not been clearly
identified, especially for total cholesterol. Here, we try to identify these causal risk factors …

Alcohol-associated liver disease (ALD) is a major cause of chronic liver disease worldwide,
and comprises a spectrum of several different disorders, including simple steatosis …

Background Nonalcoholic fatty liver disease (NAFLD) comprises hepatic alterations with
increased lipid accumulation (steatosis) without or with inflammation (nonalcoholic …

Background & Aims Genetic factors associated with non-alcoholic fatty liver disease
(NAFLD) remain incompletely understood. To date, most genome-wide association studies …

Nonalcoholic fatty liver disease (NAFLD) was first described as a distinct clinical entity four
decades ago. However, the condition has become the centre of attention within hepatology …